Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma

Targeting YAP in malignant pleural mesothelioma

(2017) Wen-Qian Zhang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

(2017) Evan W Alley et al.   LANCET ONCOLOGY

Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells

(2017) J Feng et al.   ONCOGENE

YAP/TAZ at the Roots of Cancer

(2016) Francesca Zanconato et al.   CANCER CELL

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

(2016) Nan Zhang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma

(2016) S Murakami et al.   ONCOGENE

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

(2016) Francesco Passiglia et al.   Oncotarget

YAP promotes erlotinib resistance in human non-small cell lung cancer cells

(2016) Ping-Chih Hsu et al.   Oncotarget

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression

(2015) G. Wang et al.   Cancer Discovery

Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells

(2015) Bin You et al.   Oncotarget

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

(2015) Susana Cedrés et al.   PLoS One

B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis

(2014) Aaron Scott Mansfield et al.   Journal of Thoracic Oncology

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer

(2013) C. Zielinski et al.   ANNALS OF ONCOLOGY

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

(2013) Barbara Merelli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment

(2013) Randy Johnson et al.   NATURE REVIEWS DRUG DISCOVERY